Eye specialists and Swiss company Novartis AG warned on Friday that new proposals from Britain’s cost effectiveness watchdog could deny a treatment of proven benefit to thousands of people faced with a blinding disease.
A final appraisal report by the National Institute for Clinical Excellence (NICE) recommends Visudyne photodynamic therapy for wet age-related macular degeneration for patients who have classic with no occult subfoveal neovascularisation (CNV) and visual acuity of at least 6/60.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!